Promise for glycolysis inhibitor

The multikinase inhibitor Sorafenib enhances glycolysis and synergizes with glycolysis blockade for cancer cell killing

Although the only effective drug against primary hepatocarcinoma, the multikinase inhibitor Sorafenib (SFB) usually fails to eradicate liver cancer. Since SFB targets mitochondria, cell metabolic reprogramming may underlie intrinsic tumor resistance. To characterize cancer cell metabolic response to SFB, we measured oxygen consumption, generation of reactive oxygen species (ROS) and ATP content...

Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor.

PURPOSE We sought to examine the synergistic antipancreatic cancer effect by simultaneously targeting hypoxic cancer cells with heat-shock protein 90 (HSP90) inhibitor and blockade of energy production. EXPERIMENTAL DESIGN The anticancer effects of an HSP90 inhibitor (geldanamycin) in pancreatic cells were investigated in hypoxia and normoxia. A hexokinase II inhibitor, 3-broma-pyruvate (3BrP...

medicinal plants promise new insights for management of diabetes

A PROMISE for Experimental Evaluation

Participative Research labOratory for Multimedia and Multilingual Information Systems Evaluation (PROMISE) is a Network of Excellence, starting in conjunction with this first independent CLEF 2010 conference, and designed to support and develop the evaluation of multilingual and multimedia information access systems, largely through the activities taking place in Cross-Language Evaluation Forum...

Mobile Technology’s Promise for Healthcare